StreetAlpha.app
Home › Stocks › ABBV

AbbVie Inc. (ABBV)

Healthcare
$286.20
▲ +0.94%
LAST CLOSE · NOV 20

AbbVie develops and sells prescription medicines for immunology, neuroscience and oncology, including Skyrizi and Rinvoq. It last closed at $286.20 on Nov 20, up 0.94% on the day. The next earnings report for ABBV is expected around Wed, Jan 6, 2027, after the close. For the quarter ended Sep 2026, ABBV reported EPS of $2.37 on revenue of $17.40B, with revenue up 10.3% from a year ago. Over its last 8 reports the stock moved an average of 1.9% the session after earnings. Over the last 12 months ABBV insiders bought $0 of stock on the open market and sold $30.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is ABBV in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ABBV.

Key Stats

Last 12 months
Results
Revenue
$66.0B
+10.7% vs a year ago
Net income
$10.3B
+333.1% vs a year ago
EPS (diluted)
$5.81
+340.2% vs a year ago
Free cash flow
$18.9B
28.6% margin
Valuation
Market cap
$506B
1.77B shares
P/E
49.3
Price over 12 month EPS
Price to sales
7.7
Market cap over revenue
Dividend yield
2.42%
$6.92 a share over 12 months
Balance sheet
Cash & equivalents
$10.8B
At Sep 30
Shareholder equity
−$4.6B
Buybacks
$1.5B
Last 12 months
CEORobert A. Michael
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $56.2B$56.2BFY2021FY2022: $58.1B$58.1BFY2022FY2023: $54.3B$54.3BFY2023FY2024: $56.3B$56.3BFY2024FY2025: $61.2B$61.2BFY2025

From ABBV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Jan 6
Estimated date · After the close
Reported EPS
$2.37
Quarter ended Sep 2026
Year ago EPS
$0.10
+2270.0% on a GAAP basis
Revenue
$17.40B
+10.3% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.02Dec '24Mar 2025: $0.72Mar '25Jun 2025: $0.52Jun '25Sep 2025: $0.10Sep '25Dec 2025: $1.02Dec '25Mar 2026: $0.39Mar '26Jun 2026: $2.03Jun '26Sep 2026: $2.37Sep '26Latest $2.37
Revenue by quarter
Dec 2024: $15.10BDec '24Mar 2025: $13.34BMar '25Jun 2025: $15.42BJun '25Sep 2025: $15.78BSep '25Dec 2025: $16.62BDec '25Mar 2026: $15.00BMar '26Jun 2026: $16.99BJun '26Sep 2026: $17.40BSep '26Latest $17.40B
How ABBV moved after its last 8 reports
Average move the session after a report ±1.9%
Oct 5, 2026After the close+0.3%
Jul 6, 2026After the close−0.0%
Apr 3, 2026After the close−1.0%
Jan 7, 2026After the close−4.0%
Oct 3, 2025After the close−1.6%
Jul 3, 2025After the close−0.9%
Apr 3, 2025After the close−7.3%
Jan 6, 2025After the close−0.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ABBVStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ABBV
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ABBV

Technical Analysis

ABBV · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 15% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the Pivot S1 at $283.96, and the nearest resistance the Pivot at $287.09.

Short trendNeutral
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 2.3%/day
Key levels
$302.9352 week high+5.8%
$291.40Swing high (Oct 15)+1.8%
$290.4420 day average+1.5%
$289.34Pivot R1+1.1%
$287.09Pivot+0.3%
$286.20Last close
$283.96Pivot S1−0.8%
$281.23Swing low (Oct 28)−1.7%
$279.0050 day average−2.5%
$266.75100 day average−6.8%
$242.45200 day average−15.3%
$190.7552 week low−33.4%
Indicators
RSI (14)49.19Middle of its rangeNeutral
MACD2.48Below its signal lineBearish
Stochastic22.0Middle of its rangeNeutral
ADX (14)25.1Trending up
Williams %R-72.6Oversold below −80, overbought above −20Neutral
CCI (20)-68.8Oversold below −100, overbought above 100Neutral
Rate of change−1.8%Change over 10 sessionsBearish
ATR (14)$6.70Typical daily range, 2.3% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ABBV

What happened before

See how ABBV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ABBV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ABBV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ABBVHow many large options trades hit ABBV, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ABBV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●1,924 buying vs 1,741 selling
  • ▼Held by funds -1.5 pts
  • ▲Funds holding +45
  • ▼Superinvestors: 0 added, 4 cut
  • ▲Put/call 1.38 to 1.14
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4,2884,243+1.1%
In funds' top 10201199+1.0%
Held by funds74.2%75.7%−1.5 pts
New / increased171 / 1,753229 / 1,870−8.3%
Reduced / sold out1,642 / 991,513 / 112+7.1%
Put/call ratio1.141.38−17.6%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABBV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ABBV Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$30.8M5 sales · 4 insiders
31% of the selling was under pre-arranged trading plans.
2026-02 sold $5.1M2026-03 sold $5.6M2026-08 sold $8.2M2026-11 sold $11.9MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 9Jeffrey Ryan StewartEvp, Chief Commercial OfficerSale40,619$293.60$11.9M
Aug 14Nicholas DonoghoeEvp, Chief Bus/strat OfficerSale32,710$250.00$8.2M
Mar 4David Ryan PurdueSVP, ControllerSale5,230$233.56$1.2M
Mar 2Perry C SiatisEvp, Gc And SecretarySale plan18,668$234.39$4.4M
Feb 25Perry C SiatisEvp, Gc And SecretarySale plan22,381$230.00$5.1M
Aug 12, 2025Azita Saleki-gerhardtEvp, Chief Operations OfficerSale42,370$198.42$8.4M
Every insider buy and sale for ABBV over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ABBV insider trades →

From SEC Form 4 filings by ABBV's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

ABBV Stock Buybacks

See all S&P 500 buybacks →
Spent, 12 months
$1.5B
0.3% yield
Left in program
$1.8B
0.4% of value
Shares outstanding, 12 months
+0.0%
More shares
Last quarter
$600K
Sep 2026
Avg price paid, last quarter
$249.74
2K shares bought
S&P 500 rank by spending
#135 of 358
 
Spent each quarter, last 3 yearsTop bar $1.1B
Dec 2023: $4.3M, average price $152.39Mar 2024: $959.9M, average price $180.44Jun 2024: $522K, average price $167.04Sep 2024: $495K, average price $181.35Dec 2024: $352.9M, average price $173.84Mar 2025: $606.4M, average price $213.63Jun 2025: $596K, average price $187.52Sep 2025: $600K, average price $198.16Dec 2025: $5.9M, average price $224.36Mar 2026: $1.1B, average price $230.40Jun 2026: $625K, average price $209.81Sep 2026: $600K, average price $249.74
Dec 2023Sep 2026
For membersMonth by month buying, shares and the average price paid each month are shown to AI Starter and AI Pro members.

From the company's 10-Q filed Nov 3, 2026. Quarters are the company's own fiscal quarters. Yield and % of value use the latest close. Buybacks are not a forecast: in our testing, the biggest buyers did about the same as the average S&P 500 stock.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABBV is in one of them and how their past ABBV trades turned out.

ABBV in the AI portfolios
Loading…

ABBV News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABBV in an article yet. Here's the latest on the wider market.

ABBV in the news

ABBV Congress Trades

All congress trades →
Trades, 12 months
11
Buys
4
36%
Sells
7
64%
People
6
Last filed Nov 5
Who traded ABBV · since 2013
Latest 5 filings of 174
$15K – $50KTraded Oct 7, 2026Filed Nov 5, 2026
Ro KhannaSell (partial)
$15K – $50KTraded Sep 4, 2026Filed Oct 7, 2026
$15K – $50KTraded Sep 14, 2026Filed Sep 18, 2026
$15K – $50KTraded Mar 27, 2026Filed Jul 21, 2026
$1K – $15KTraded May 5, 2026Filed Jun 3, 2026
PersonTypeAmountTradedFiledDelay
Ro KhannaD · CABuy$15K – $50KOct 7, 2026Nov 5, 202629 d
Ro KhannaD · CASell (partial)$15K – $50KSep 4, 2026Oct 7, 202633 d
Pete SessionsR · TXSell$15K – $50KSep 14, 2026Sep 18, 20264 d
Alan ArmstrongR · OKBuy$15K – $50KMar 27, 2026Jul 21, 2026116 d
Josh GottheimerD · NJSell$1K – $15KMay 5, 2026Jun 3, 202629 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About AbbVie

AbbVie is a biopharmaceutical company based in North Chicago, Illinois. It researches, develops, manufactures and sells prescription medicines in immunology, neuroscience and oncology, including Skyrizi, Rinvoq and Botox Therapeutic. Its treatments are used by patients with autoimmune diseases, migraine, Parkinson's disease and several blood cancers. The company sells its products in many countries around the world.

Headquarters
North Chicago, IL
Founded
2012